435 related articles for article (PubMed ID: 27791031)
1. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
3. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
4. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
7. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
8. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.
Fu X; Huang C; Schiff R
Breast Cancer Res; 2011 Apr; 13(2):307. PubMed ID: 21575280
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
10. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
11. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
12. Bisphenol A stimulates the epithelial mesenchymal transition of estrogen negative breast cancer cells via FOXA1 signals.
Zhang XL; Wang HS; Liu N; Ge LC
Arch Biochem Biophys; 2015 Nov; 585():10-16. PubMed ID: 26363213
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
14. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
Wolf I; Bose S; Williamson EA; Miller CW; Karlan BY; Koeffler HP
Int J Cancer; 2007 Mar; 120(5):1013-22. PubMed ID: 17163418
[TBL] [Abstract][Full Text] [Related]
15. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
16. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
17. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
18. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
Ross-Innes CS; Stark R; Teschendorff AE; Holmes KA; Ali HR; Dunning MJ; Brown GD; Gojis O; Ellis IO; Green AR; Ali S; Chin SF; Palmieri C; Caldas C; Carroll JS
Nature; 2012 Jan; 481(7381):389-93. PubMed ID: 22217937
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 represses the molecular phenotype of basal breast cancer cells.
Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
[TBL] [Abstract][Full Text] [Related]
20. USP9X downregulation renders breast cancer cells resistant to tamoxifen.
Oosterkamp HM; Hijmans EM; Brummelkamp TR; Canisius S; Wessels LF; Zwart W; Bernards R
Cancer Res; 2014 Jul; 74(14):3810-20. PubMed ID: 25028367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
